Abstract
Aim:
To investigate anticancer activity of the DNA binding domain of SMAR1 (His 5) in vitro and in vivo.
Materials & methods:
His 5 was conjugated to hydrothermally synthesized carbon nanospheres (CNs). Anticancer activity of CNs-His 5 was evaluated in vitro and in vivo.
Results:
CNs- His 5 significantly reduced cyclin D1 levels in MDA-MB-231 cells. Tumor bearing Balb/c mice injected with CNs-His 5 showed approximately 62% tumor regression and significantly reduced 18FDG uptake. Caspases assay and IHC staining confirmed tumor growth inhibition, which could be attributed to apoptotic, antiproliferative and antiangiogenic activities of His 5.
Conclusion:
DNA binding domain of the SMAR1 protein (His 5) has potent anticancer activity and its CNs mediated delivery could control breast tumor in mice model.
Keywords:
DNA binding domain; PET; SMAR1; breast cancer; carbon nanospheres.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / chemistry*
-
Apoptosis / drug effects
-
Breast Neoplasms / drug therapy*
-
Carbon / chemistry*
-
Cell Cycle Proteins / administration & dosage*
-
Cell Cycle Proteins / metabolism
-
Cell Line, Tumor
-
Cell Survival / drug effects
-
Cyclin D1 / metabolism
-
DNA-Binding Proteins / administration & dosage*
-
DNA-Binding Proteins / metabolism
-
Drug Carriers / chemistry*
-
Drug Liberation
-
Female
-
Humans
-
Mice, Inbred BALB C
-
Nanospheres / chemistry*
-
Nuclear Proteins / administration & dosage*
-
Nuclear Proteins / metabolism
-
Protein Domains
-
Recombinant Proteins / administration & dosage
-
Tissue Distribution
Substances
-
Antineoplastic Agents
-
BANP protein, human
-
CCND1 protein, human
-
Cell Cycle Proteins
-
DNA-Binding Proteins
-
Drug Carriers
-
Nuclear Proteins
-
Recombinant Proteins
-
Cyclin D1
-
Carbon